6RC Stock Overview
Provides stem cell research and drug discovery services in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
ReproCELL Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥0.67 |
| 52 Week High | JP¥1.38 |
| 52 Week Low | JP¥0.37 |
| Beta | 0.78 |
| 1 Month Change | 8.13% |
| 3 Month Change | -14.19% |
| 1 Year Change | 3.91% |
| 3 Year Change | -55.67% |
| 5 Year Change | -80.33% |
| Change since IPO | -95.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6RC | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -5.0% | 1.1% | 3.4% |
| 1Y | 3.9% | -14.9% | 15.0% |
Return vs Industry: 6RC exceeded the German Biotechs industry which returned -14.9% over the past year.
Return vs Market: 6RC underperformed the German Market which returned 14.4% over the past year.
Price Volatility
| 6RC volatility | |
|---|---|
| 6RC Average Weekly Movement | 16.8% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 6RC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6RC's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 96 | Shuji Yokoyama | www.reprocell.com |
ReproCELL Incorporated provides stem cell research and drug discovery services in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, pluripotent stem cells, and synfire induced neurons; 3D cell culture; and labware. The company also provides research stem cell, genomics, clinical stem cell research, preclinical and drug discovery CRO, precision medicine, human tissue samples, clinical laboratory, diagnostic, and gene editing services.
ReproCELL Incorporated Fundamentals Summary
| 6RC fundamental statistics | |
|---|---|
| Market cap | €82.64m |
| Earnings (TTM) | -€675.98k |
| Revenue (TTM) | €16.70m |
4.9x
P/S Ratio-122.2x
P/E RatioIs 6RC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6RC income statement (TTM) | |
|---|---|
| Revenue | JP¥2.72b |
| Cost of Revenue | JP¥1.30b |
| Gross Profit | JP¥1.42b |
| Other Expenses | JP¥1.53b |
| Earnings | -JP¥110.00m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 14, 2025
| Earnings per share (EPS) | -1.16 |
| Gross Margin | 52.06% |
| Net Profit Margin | -4.05% |
| Debt/Equity Ratio | 0% |
How did 6RC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/05 12:25 |
| End of Day Share Price | 2025/05/05 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ReproCELL Incorporated is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Akinori Ueda | Goldman Sachs |